World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
147
Citations
130176
World Ranking
1249
National Ranking
726

Daniel F. Hayes publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Daniel F. Hayes sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 688 publications — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Daniel F. Hayes D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Daniel F. Hayes sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 147 D-Index — 94th percentile

94% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Daniel F. Hayes is affiliated with the University of Michigan-Ann Arbor in the United States. Their research primarily focuses on areas within medicine and biochemistry, genetics, and molecular biology, with significant contributions to oncology, cancer research, pulmonary and respiratory medicine, genetics, and molecular biology subfields.

The scientist has published extensively on topics related to breast cancer treatment studies, advanced breast cancer therapies, and cancer genomics and diagnostics. Other highlighted topics include cancer cells and metastasis, cancer treatment and pharmacology, estrogen and related hormone effects, and HER2/EGFR in cancer research.

Their recent published papers include:

  • Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update, 2020, Journal of Clinical Oncology
  • Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group, 2020, JNCI Journal of the National Cancer Institute
  • Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update, 2023, Journal of Clinical Oncology
  • Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update, 2020, Archives of Pathology & Laboratory Medicine
  • Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors, 2021, JAMA Oncology

Daniel F. Hayes often collaborates with several coauthors, notably William E. Barlow, James M. Rae, Kathy S. Albain, Gabriel N. Hortobágyi, and Lajos Pusztai, each with numerous joint publications, reflecting ongoing collaborative research efforts.

The main publication venues for their work include:

  • Journal of Clinical Oncology
  • Cancer Research
  • UNC Libraries
  • JNCI Journal of the National Cancer Institute
  • Breast Cancer Research and Treatment

Daniel F. Hayes has been recognized as a member of the Association of American Physicians.

Best Publications

  • American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

    M. Elizabeth H. Hammond;Daniel F Hayes;Mitch Dowsett;D Craig Allred

  • American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

    Antonio C. Wolff;M. Elizabeth H. Hammond;Jared N. Schwartz;Karen L. Hagerty

  • Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer

    Massimo Cristofanilli;G. Thomas Budd;Matthew J. Ellis;Alison Stopeck

  • American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

    Antonio C. Wolff;M. Elizabeth H. Hammond;Jared N. Schwartz;Karen L. Hagerty

  • ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.

    Christophe Ginestier;Min Hee Hur;Emmanuelle Charafe-Jauffret;Florence Monville

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

    Lyndsay Harris;Herbert Fritsche;Robert Mennel;Larry Norton

  • Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

    Mitch Dowsett;Torsten O. Nielsen;Roger A’Hern;John Bartlett

  • Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

    Joseph A. Sparano;Robert J. Gray;Della F. Makower;Kathleen I. Pritchard

  • EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

    Celina G. Kleer;Qi Cao;Sooryanarayana Varambally;Ronglai Shen

  • ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer

    Gershon Y. Locker;Stanley R Hamilton;Jules Harris;John M. Jessup

  • Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

    Kathy S Albain;William E Barlow;Steven Shak;Gabriel N Hortobagyi

  • Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

    I. Craig Henderson;Donald A. Berry;George D. Demetri;Constance T. Cirrincione

  • American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

    Carmen J. Allegra;Carmen J. Allegra;J. Milburn Jessup;Mark R. Somerfield;Stanley R. Hamilton

  • Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

    Mark D. Pegram;Allen Lipton;Daniel F. Hayes;Barbara L. Weber

  • Revision of the American Joint Committee on Cancer Staging System for Breast Cancer

    S. Eva Singletary;Craig Allred;Pandora Ashley;Lawrence W. Bassett

  • Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.

    Fitzgibbons Pl;Page Dl;Weaver D;Thor Ad

  • Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review

    Jason D. Merker;Geoffrey R. Oxnard;Carolyn Compton;Maximilian Diehn

  • Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

    J. A. Sparano;R. J. Gray;D. F. Makower;K. I. Pritchard

  • 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

    Hongchao Pan;Richard Gray;Jeremy Braybrooke;Christina Davies

Frequent Co-Authors

Vered Stearns
Vered Stearns Johns Hopkins University
William E. Barlow
William E. Barlow Fred Hutchinson Cancer Research Center
Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
David A. Flockhart
David A. Flockhart Indiana University
Kathy S. Albain
Kathy S. Albain Loyola University Chicago
Antonio C. Wolff
Antonio C. Wolff Johns Hopkins University
Mitch Dowsett
Mitch Dowsett Breast Cancer Research Foundation
Giuseppe Viale
Giuseppe Viale University of Milan
Lori J. Pierce
Lori J. Pierce University of Michigan–Ann Arbor
Robert B. Livingston
Robert B. Livingston University of Arizona

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in Medicine but looking for alternative or supportive career paths, there are a variety of online degree programs worth considering. Online nursing degrees, for example, have become a popular and flexible option for those entering or advancing in the healthcare field.

For individuals seeking entry-level qualifications, online nursing programs provide a practical route to becoming a licensed nurse, combining affordability with schedule flexibility. Those who are already registered nurses and want to enhance their credentials can benefit from the cheapest online RN to BSN programs, allowing them to earn a bachelor’s degree while continuing to work.

For advanced clinical practice, affordable NP programs offer a pathway to become a nurse practitioner, an in-demand role with expanded responsibilities. Ambitious professionals interested in research or academic leadership may explore online PhD nursing programs to build expertise and open new career doors.

Exploring these online pathways can help you tailor your medical career, align with personal goals, and manage costs more efficiently.

Best Scientists Citing Daniel F. Hayes

Trending Scientists